Immunohistochemical Expression of Signal Transducer and Activator of Transcription (STAT6) in Classic Hodgkin Lymphoma (CHL)

STAT6 in Classic Hodgkin Lymphoma

Authors

  • Tabish Hassan Department of Histopathology, PNS Shifa, Karachi, Pakistan
  • Nadeem Zafar Department of Histopathology, CMH Lahore, Pakistan
  • Nighat Jamal Department of Histopathology, PEMH Rawalpindi, Pakistan
  • Akhtar Ali Bajwa Department of Histopathology, PNS Shifa, Karachi, Pakistan
  • Rabia Ahmad Department of Histopathology, PNS Shifa, Karachi, Pakistan
  • Rabeea Zubair Department of Dermatology, Jinnah Hospital, Lahore, Pakistan

DOI:

https://doi.org/10.61919/jhrr.v4i3.1404

Keywords:

STAT 6, Hodgkin lymphoma, Carcinoma

Abstract

Background: Hodgkin lymphoma (HL) is a significant malignancy, with Classic Hodgkin Lymphoma (CHL) and Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) being its main subtypes. STAT6, a transcription factor in the IL-4/IL-13 pathway, may aid in distinguishing between these subtypes through immunohistochemical analysis.
Objective: To evaluate the diagnostic utility of STAT6 immunohistochemical expression in differentiating CHL from NLPHL.
Methods: A comparative cross-sectional study was conducted on 94 lymphoma cases, including 53 CHL and 41 NLPHL cases. Tissue samples were fixed, processed, and stained with STAT6 antibody. Nuclear and cytoplasmic STAT6 expression was assessed in neoplastic cells. Statistical analysis was performed using SPSS version 25, with Fisher’s exact test applied.
Results: Nuclear STAT6 expression was observed in 100% of CHL cases (53/53) and in 24.39% of NLPHL cases (10/41). Combined nuclear and cytoplasmic STAT6 expression was present in all CHL cases (53/53) but absent in NLPHL cases (0/41).
Conclusion: STAT6 nuclear expression serves as a reliable marker to distinguish CHL from NLPHL, with a 100% negative predictive value for NLPHL.

Downloads

Download data is not yet available.

References

Shabbir S, Ahmed KN, Marri M, Mengal M, Jan MH, Jamali MS, et al. 6. Epidemiological features of Lymphoma in Pakistan. Pure and Applied Biology (PAB). 2019;8(1):977-94.

Mani H, Jaffe ES. Hodgkin lymphoma: an update on its biology with new insights into classification. Clinical Lymphoma and Myeloma. 2009;9(3):206-16.

Jiang M, Bennani NN, Feldman AL. Lymphoma classification update: T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms. Expert Rev Hematol. 2017;10(3):239-49.

Lee AI, LaCasce AS. Nodular lymphocyte predominant Hodgkin lymphoma. The oncologist. 2009;14(7):739-51.

Eichenauer DA, Engert A. How I treat nodular lymphocyte-predominant Hodgkin lymphoma. Blood, The Journal of the American Society of Hematology. 2020;136(26):2987-93.

Andrade-Gonzalez X, Ansell SM. Novel therapies in the treatment of hodgkin lymphoma. Curr Treat Options Oncol. 2021;22(5):42.

Chan WC. The Reed–Sternberg cell in classical Hodgkin's disease. Hematol Oncol. 2001;19(1):1-17.

Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner H-H, Bartlett NL. Hodgkin lymphoma. Nature Reviews Disease Primers. 2020;6(1):61.

Song JY, Eberle FC, Xi L, Raffeld M, Rahma O, Wilson WH, et al. Coexisting and clonally identical classic hodgkin lymphoma and nodular lymphocyte predominant hodgkin lymphoma. The American journal of surgical pathology. 2011;35(5):767-72.

Skinnider BF, Elia AJ, Gascoyne RD, Trümper LH, Von Bonin F, Kapp U, et al. Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood, The Journal of the American Society of Hematology. 2001;97(1):250-5.

Guiter C, Dusanter-Fourt I, Copie-Bergman C, Boulland M-L, Le Gouvello S, Gaulard P, et al. Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. Blood. 2004;104(2):543-9.

Israel GD. Determining sample size. 1992.

Parente P, Zanelli M, Sanguedolce F, Mastracci L, Graziano P. Hodgkin Reed–Sternberg-Like Cells in Non-Hodgkin Lymphoma. Diagnostics. 2020;10(12):1019.

Natoli A, Lüpertz R, Merz C, Müller WW, Köhler R, Krammer PH, Li‐Weber M. Targeting the IL‐4/IL‐13 signaling pathway sensitizes Hodgkin lymphoma cells to chemotherapeutic drugs. Int J Cancer. 2013;133(8):1945-54.

Van Slambrouck C, Huh J, Suh C, Song JY, Menon MP, Sohani AR, et al. Diagnostic utility of STAT6YE361 expression in classical Hodgkin lymphoma and related entities. Mod Pathol. 2020;33(5):834-45.

Babar N, Mushtaq S, Mahmood MT, Ahmed AH, Hussain M, Hassan U. Role of Gata3 and stat6 immunohistochemistry in classic hodgkin lymphoma (CHL) and nodular lymphocyte predominant hodgkin lymphoma (NLPHL). Pakistan Journal of Pathology. 2023;34(3):63-7.

Downloads

Published

2024-08-28

How to Cite

Tabish Hassan, Nadeem Zafar, Nighat Jamal, Akhtar Ali Bajwa, Rabia Ahmad, & Rabeea Zubair. (2024). Immunohistochemical Expression of Signal Transducer and Activator of Transcription (STAT6) in Classic Hodgkin Lymphoma (CHL): STAT6 in Classic Hodgkin Lymphoma . Journal of Health and Rehabilitation Research, 4(3), 1–4. https://doi.org/10.61919/jhrr.v4i3.1404

Issue

Vol. 4 No. 3 (2024): Volume 4, Issue 3 - July to September 2024

Section

Articles

License

Copyright (c) 2024 Tabish Hassan, Nadeem Zafar, Nighat Jamal, Akhtar Ali Bajwa, Rabia Ahmad, Rabeea Zubair

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.